España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Protagonist Therapeutics
PTGX
NASDAQ
Watchlist
Get Report
Perks
Buy
Compare Brokers
$33.72
-0.78
-2.26%
At Close: -
$33.72
0
0.00%
After Hours: Jul 5, 4:00 PM EDT
15 minutes delayed
Get Report
Watch
Protagonist Therapeutics (PTGX) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Protagonist Therapeutics (NASDAQ:PTGX) Stock
Protagonist Therapeutics Stock (NASDAQ: PTGX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, June 28, 2024
Market-Moving News for June 28th
Benzinga Newsdesk
Protagonist Therapeutics shares are trading h...
Benzinga Newsdesk
Thursday, June 27, 2024
Protagonist Therapeutics To Join S&P SmallCap...
Benzinga Newsdesk
Monday, June 17, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Friday, June 14, 2024
HC Wainwright & Co. Reiterates Buy on Protago...
Benzinga Newsdesk
Protagonist Presents Updated Long-Term Findin...
Benzinga Newsdesk
Tuesday, May 14, 2024
Protagonist Therapeutics Presents Long-Term F...
Benzinga Newsdesk
Thursday, May 09, 2024
HC Wainwright & Co. Reiterates Buy on Protago...
Benzinga Newsdesk
Wednesday, May 08, 2024
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Tuesday, May 07, 2024
Protagonist Therapeutics Q1 EPS $3.26, Sales ...
Benzinga Newsdesk
Tuesday, March 26, 2024
Protagonist Therapeutics Has Randomized 241 P...
Benzinga Newsdesk
Monday, March 18, 2024
Protagonist Therapeutics Closes Worldwide Rus...
Benzinga Newsdesk
Monday, March 11, 2024
HC Wainwright & Co. Maintains Buy on Protagon...
Benzinga Newsdesk
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Protagonist Therapeutics Announced A Late-bre...
Benzinga Newsdesk
Wednesday, February 28, 2024
JP Morgan Maintains Overweight on Protagonist...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Protago...
Benzinga Newsdesk
Tuesday, February 27, 2024
Protagonist Therapeutics Q4 2023 GAAP EPS $0....
Benzinga Newsdesk
Wednesday, February 21, 2024
Protagonist Therapeutics Publishes Results Of...
Benzinga Newsdesk
Thursday, February 01, 2024
Protagonist Therapeutics shares are trading h...
Benzinga Newsdesk
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
Vandana Singh
Wednesday, January 31, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
Protagonist Therapeutics shares are trading h...
Benzinga Newsdesk
Takeda And Protagonist Therapeutics, Inc. Ent...
Benzinga Newsdesk
Wednesday, December 13, 2023
Protagonist Therapeutics Earned $10M Mileston...
Benzinga Newsdesk
Tuesday, December 12, 2023
Protagonist Reports 2-Year Follow Up Data Fro...
Benzinga Newsdesk
Friday, November 03, 2023
The Latest Analyst Ratings for Protagonist Therapeutics
Benzinga Insights
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Thursday, November 02, 2023
Protagonist Therapeutics Announces Abstracts ...
Benzinga Newsdesk
Tuesday, October 31, 2023
Board Member at Protagonist Therapeutics Acquires Company Stock Options Worth 45,000 Shares
Benzinga Insights
Monday, October 30, 2023
Capital One Initiates Coverage On Protagonist...
Benzinga Newsdesk
Tuesday, October 24, 2023
Chief Development Officer at Protagonist Therapeutics Exercises Options Worth $281K
Benzinga Insights
Friday, October 20, 2023
President and CEO at Protagonist Therapeutics Exercises Options Worth $87K
Benzinga Insights
Tuesday, October 10, 2023
HC Wainwright & Co. Reiterates Buy on Protago...
Benzinga Newsdesk
Monday, October 09, 2023
Protagonist Announces Advancement of JNJ-2113...
Benzinga Newsdesk
Monday, September 25, 2023
What 6 Analyst Ratings Have To Say About Protagonist Therapeutics
Benzinga Insights
JP Morgan Maintains Overweight on Protagonist...
Benzinga Newsdesk
Friday, August 04, 2023
HC Wainwright & Co. Reiterates Buy on Protago...
Benzinga Newsdesk
Thursday, August 03, 2023
Protagonist Therapeutics Q2 EPS $(0.68) Misse...
Benzinga Newsdesk
Thursday, July 27, 2023
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Lisa Levin
Monday, July 10, 2023
HC Wainwright & Co. Reiterates Buy on Protago...
Benzinga Newsdesk
Thursday, July 06, 2023
Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive
Vandana Singh
Expert Ratings for Protagonist Therapeutics
Benzinga Insights
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Lisa Levin
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Wednesday, July 05, 2023
Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment
Vandana Singh
Tuesday, July 04, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
Monday, July 03, 2023
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Session
Lisa Levin
Piper Sandler Reiterates Overweight on Protag...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch